Article Text

Download PDFPDF
Prognostic Value of Human Epidermal Growth Factor Receptor 2 (Her-2)/neu in Patients With Advanced Ovarian Cancer Treated With Platinum/Paclitaxel as First-Line Chemotherapy: A Retrospective Evaluation of the AGO-OVAR 3 Trial by the AGO OVAR Germany
  1. Jacobus Pfisterer*,
  2. Andreas Du Bois,
  3. Eva-Katrin Bentz*,,
  4. Friedrich Kommoss§,
  5. Philipp Harter,
  6. Jens Huober,
  7. Barbara Schmalfeldt,
  8. Nicole Burchardi**,
  9. Norbert Arnold* and
  10. Felix Hilpert*
  1. * Klinik für Gynäkologie und Geburtshilfe, Universitätsklinikum Schleswig-Holstein, Campus Kiel, Kiel, Germany;
  2. Klinik für Gynäkologie und Gynäkologische Onkologie, HSK Dr Horst Schmidt Klinik, Wiesbaden, Germany;
  3. Universitätsklinik für Frauenheilkunde, Wien, Austria;
  4. § Institut für Pathologie, Mannheim, Germany;
  5. Senologiezentrum Ostschweiz SENZO, Kantonsspital St, Gallen, Switzerland;
  6. Frauenklinik, Universitätsklinikum rechts der Isar, München, Germany; and
  7. ** Koordinierungszentrum für Klinische Studien, Philipps-Universität, Marburg, Germany.
  1. Address correspondence and reprint requests to Felix Hilpert, Universitätsklinikum Schleswig-Holstein, Campus Kiel, Michaelisstrasse 16, 24105 Kiel, Germany. E-mail: fhilpert{at}


Objectives: Results on the prognostic value of human epidermal growth factor receptor 2 (HER-2)/neu in ovarian cancer are inconsistent. This exploratory analysis evaluates Her-2/neu as a prognostic factor in a large cohort of patients with advanced-stage ovarian cancer treated with platinum/paclitaxel as first-line chemotherapy within a prospective randomized trial.

Methods: Her-2/neu expression was assessed by immunohistochemistry in 359 patients (46%) treated within the AGO-OVAR 3 trial (n = 783). Patients received either cisplatin/paclitaxel or carboplatin/paclitaxel according to the study protocol. Immunohistochemistry results were scored according to the Dako score.

Results: Her-2/neu Dako scores of 0 or 1+ was found in 337 patients (94%) and a score of 2+ or 3+ in 22 patients (6%). Her-2/neu overexpression (2+/3+) was associated with a higher International Federation of Gynecology and Obstetrics stage and larger postoperative residual disease. There were no significant differences in response to chemotherapy between the Her-2/neu score subgroups and in progression-free survival time. In a multivariate analysis, the Her-2/neu score had no significant impact on overall survival time.

Conclusions: In the present study, Her-2/neu overexpression in patients with advanced-stage ovarian cancer was rare and provided no evidence for a prognostic value of Her-2/neu in patients with advanced ovarian cancer treated with platinum/paclitaxel.

  • Ovarian cancer
  • Platinum/paclitaxel
  • Her-2/neu

Statistics from

Request Permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.